Pomegra
Function Health secured $450 million in non-dilutive growth financing from General Catalyst's Customer Value Fund, adding to a $298 million Series B raised just eight months earlier as the Austin company races to scale preventive lab testing and imaging across the U.S.
Key Takeaways
- Function Health raised $450M in non-dilutive growth capital from General Catalyst's Customer Value Fund in mid-2026.
- The deal preserves Function's $2.5B valuation set at its November 2025 Series B; total capital raised now exceeds $800M.
- The company offers members 100+ lab tests plus AI-powered MRI and CT imaging; it has made three acquisitions since May 2025.
Lead
Function Health, the Austin-based preventive care platform co-founded by CEO Jonathan Swerdlin and physician Mark Hyman, announced $450 million in growth financing from General Catalyst's Customer Value Fund (CVF) in late July 2026. The round - structured as non-dilutive, revenue-linked capital rather than equity - does not reset the company's $2.5 billion valuation established in its November 2025 Series B. With the new capital, Function has raised over $800 million since it began operations in 2023.
What Does Function Health Actually Do?
Function sells membership-based access to preventive health diagnostics. Members receive over 100 lab tests covering hormones, cardiovascular markers, metabolic panels, cancer-screening biomarkers, and more - plus access to AI-assisted MRI and CT imaging. The company's $899 full-body MRI scan, introduced after its May 2025 acquisition of Ezra, has been one of its most visible offerings.
The model sidesteps traditional insurance: Function charges members directly and does not provide treatment, pairing results with clinician-guided insights and recommendations. The pitch is early detection - catching disease markers before symptoms appear - at a price point accessible to consumers outside a clinical visit.
What Is General Catalyst's Customer Value Fund, and Why Does the Structure Matter?
The CVF is General Catalyst's non-dilutive capital vehicle designed for companies with recurring, predictable revenue. Rather than taking equity, the fund is repaid as a function of customer growth and revenue performance. For Function, this means the $450 million injection doesn't trigger a down round or an up round - it is off the equity cap table entirely.
That structure is meaningful context. Function's equity valuation at the Series B was $2.5 billion. A traditional equity round at that same or higher valuation would have required demonstrating that growth since November 2025 justified the price. Using CVF capital lets Function draw substantial resources without that public test of its equity value - useful when scaling costs are high and the company is still building toward profitability.
General Catalyst has been deepening its bet on health-tech infrastructure broadly. The CVF vehicle has been used with other high-revenue-growth companies where the firm wants to accelerate scale without compressing equity stakes.
How Fast Is Function Scaling?
The company's acquisition pace tells part of the story. In the twelve months ending May 2026, Function completed three deals: Ezra (AI-enabled full-body MRI, May 2025), Getlabs (at-home specimen collection logistics, April 2026), and SuppCo (supplement intelligence platform, May 2026). Each fills a gap in the vertical stack - imaging, sample collection, and supplementation guidance - rather than adding overlapping capabilities.
That acquisition strategy reflects where Function's model hits friction: the at-home or clinic-adjacent collection process is a logistical chokepoint, and Getlabs addresses it directly. Scaling imaging nationwide requires infrastructure, not just partnerships. The company is not simply growing memberships; it is building the operational layer to fulfill those memberships in more markets.
Does the Capital Signal Anything About the Preventive Health Market?
Investor appetite for this category has grown sharply. The direct-to-consumer lab testing market was marginal a decade ago; Function's growth - and General Catalyst's willingness to commit $450 million in a single financing - reflects both category maturation and continued consumer demand for health visibility outside a doctor's office. Whether that demand translates into durable retention at meaningful scale remains the open question for the business model.
Preventive health as a category also carries a systemic argument: early detection should, in theory, reduce downstream treatment costs. That thesis has been consistent in health-tech fundraising pitches for years. The harder test is whether payers, employers, or individuals will finance that early detection consistently enough to produce the unit economics the thesis requires.
Outlook
Function enters the second half of 2026 with substantial capital, a growing service menu, and three recently integrated acquisitions to digest. The CVF structure buys runway without equity dilution, but it also ties repayment to revenue performance - meaning execution on member growth will directly determine the cost of the capital. The company's trajectory from launch to $800 million raised in under four years reflects genuine market interest in the model. Whether Function can convert that into a self-sustaining national health platform - not just a well-funded one - is the test the next phase of growth will answer.
